Should inoperable squamous cell carcinoma of the esophagus be treated to doses > 60 Gy?  

Should the recent publication of Chen et al. dose escalation study for inoperable SCC esophageal cancer patients treated with CCRT, showing an 8% 5-year OS benefit for high-dose RT (>=60 Gy) versus standard dose (50-50.4 Gy) change current real-world practice for carefully selected patients? Or should we adhere to 50-50.4 Gy until RCT results from prospective trials become available? 



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution